Clinical Trials Browser

Phase 3 × lenvatinib × Head & Neck × Clear all

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3 Completed

112 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT04199104 2025-04-23

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck

NCT01321554 2023-06-22

SELECT

Phase 3 Completed

392 enrolled 10 charts

Thyroid Neoplasms